Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 7:22 PM
Ignite Modification Date: 2025-12-24 @ 7:22 PM
NCT ID: NCT01391403
Eligibility Criteria: Inclusion Criteria: * Currently resides in Beijing, China * Diagnosis of schizophrenia or schizophreniform disorder * Duration of symptoms is no longer than 60 months * No history of treatment with antipsychotic medication or, if previously treated, a total lifetime usage of less than 14 days * Current psychotic symptoms are of moderate severity or greater as measured by one of the five psychotic items in the Brief Psychiatric Rating Scale (BPRS) Exclusion Criteria: * DSM-IV Axis I diagnosis other than schizophrenia or schizophreniform psychosis * Documented disease of the central nervous system that might interfere with the trial assessments (e.g., stroke, tumor, Parkinson's disease, Huntington's disease, seizure disorder, history of brain trauma resulting in significant impairment, chronic infection) * Acute, unstable, and/or significant and untreated medical illness (e.g., infection, unstable diabetes, uncontrolled hypertension) * A clinically significant echocardiogram (ECG) abnormality in the opinion of the investigator * Pregnant or breastfeeding * Use of prohibited concomitant therapy * History of severe allergy or hypersensitivity * Dependence on alcohol or illegal drugs * Use of any of the following medications during the trial: antipsychotic medications other than risperidone; psychostimulants; or antidepressants
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 65 Years
Study: NCT01391403
Study Brief:
Protocol Section: NCT01391403